Clinical advisory board
Opthea's Clinical Advisory Board provides insight into the regulatory and clinical development strategy for OPT-302.
The four founding members are internationally recognised clinicians and eye disease specialists who have been involved in the development of a number of leading ophthalmic drugs including Macugen®, Fovista®, Eylea® and Lucentis®.
Dr Pravin Dugel is Managing Partner of Retinal Consultants of Arizona and a Founding Member of the Spectra Eye Institute. He is also Clinical Professor at the Department of Ophthalmology at the Keck School of Medicine, University of Southern California. Dr Dugel is globally recognised as a clinical researcher, having served as Principal Investigator for over 50 multicentre clinical trials for emerging and FDA-approved therapies for wet AMD including Fovista®, Lucentis® and Eylea®. The Becker Institute recently named him “one of the best 35 ophthalmologists in the United States”.
Prof Mark Gillies is a retinal clinician with a distinguished 25-year history in the research of retinal disease. The first Australian ophthalmologist to be awarded a PhD, he studied in Boston and London before joining the University of Sydney’s Save Sight Institute, where he leads the Macular Research Group. He has been a scientific advisor to the Macular Photocoagulation Study Group, the world’s leading investigator-initiated study group for retinal diseases, and is currently Scientific Manager of the MacTel Project, an international project to identify a cure for Macular Telangiectasia Type 2.
Dr Peter Campochiaro is the George S. and Dolores Dor Eccles Professor of Ophthalmology and Neuroscience at the John Hopkins Wilmer Eye Institute. A highly respected clinical researcher with a particular expertise in ocular neovascularisation and vascular leakage, his laboratory research group helped to demonstrate the importance of the vascular endothelial growth factor (VEGF) pathway in retinal and choroidal vascular diseases. As a clinician he has had significant experience in many of the clinical studies evaluating anti-VEGF-A therapies including Lucentis® and Eylea®.
Dr Kameran Lashkari holds several academic positions including Clinical Assistant Scientist at the Schepens Eye Research Institute and Clinical Instructor of Ophthalmology at Harvard Medical School. He has completed a research fellowship at the Schepens Institute and medical and surgical fellowships in vitreoretinal disease at Harvard Medical School and the Massachusetts Eye and Ear Infirmary, where he serves as Assistant in Ophthalmology. He is currently conducting research into the pathophysiology of AMD including the response of patients with wet AMD to anti-VEGF therapy.
Opthea's key advisors in ophthalmology also include Dr Emmett Cunningham (Ophthalmologist & Chairman of the Ophthalmology Innovation Summit and formerly Senior VP Medical Strategy at Eyetech), Dr Denis O'Shaughnessy (formerly Senior VP Clinical Affairs at Oraya Therapeutics, clinical consultant to Xcovery Vision and founding member of Eyetech), Dr David Worsley (Retinal Ophthalmologist, Hamilton Eye Clinic, New Zealand) and Dr Robert Finger (Retinal Ophthalmologist, Royal Victorian Eye and Ear Hospital and Centre for Eye Research Australia).